Skip to main content
. 2024 Nov 12;16(11):e73531. doi: 10.7759/cureus.73531

Table 2. Comparison of covariates by lipid-lowering therapy (LLT) treatment status; differences in the observations were assessed using Pearson’s Chi-square test of proportions at a 5% significance level.

ACEi: angiotensin-converting enzyme inhibitors; ARBs: aldosterone receptor blockers; COPD: chronic obstructive pulmonary diseases; HIV:  human immunodeficiency virus

  No LLT (n = 499 (36.9%)) LLT prescribed (n = 855  (63.1%)) p-value Test statistic
Variable n (%) n (%)   χ 2 test
Age category     0.15 2.07
Less than 73 years 270 (54.1) 428 (50.1)    
73 years and above 229 (45.9) 427 (49.9)    
Sex        
Female 213 (42.7) 328 (38.4) 0.12 2.45
Male 286 (57.3) 527 (61.6)    
Comorbid conditions        
Atrial fibrillation/flutter 149 (29.9) 342 (40.0) <0.001 14.02
Alcohol use 166 (33.3) 224 (28.5) 0.07 3.34
Cancer 151 (30.3) 260 (30.4) 0.95 0.0033
Chronic renal failure 145 (29.1) 379 (44.3) <0.001 30.97
COPD 172 (34.5) 351 (41.) 0.02 5.76
Diabetes 125 (25.1) 420 (49.1) <0.001 75.93
Heart failure 121 (24.2) 298 (34.8) <0.001 16.58
HIV 7 (1.4) 2 (0.2) 0.01 6.52
Hyperlipidemia 122 (24.4) 656 (76.7) <0.001 352.28
Hypertension 328 (65.7) 743 (86.9) <0.001 85.41
Illicit drug use 26 (5.2) 30 (3.5) 0.13 2.30
Lupus 7 (1.4) 5 (0.6) 0.14 2.40
Obesity 93 (18.7) 223 (26.1) 0.002 9.76
Peripheral arterial disease 52 (10.4) 186 (21.7) <0.001 27.94
Rheumatoid arthritis 15 (3.0) 32 (3.7) 0.48 0.51
Sleep apnea 58 (11.6) 167 (19.5) <0.001 14.22
Tobacco use 307 (61.5) 561 (65.6) 0.13 2.29
Chronic medications        
ACEi/ARBs 200 (40.1) 610 (71.3) <0.001 128.15
Anticoagulants 148 (29.7) 356 (41.6) <0.001 19.35
Antiplatelets 187 (37.5) 639 (74.7) <0.001 183.91
Beta-blockers 216 (43.3) 621 (72.6) <0.001 114.96
Calcium channel blockers 167 (33.5) 398 (46.5) <0.001 22.18
Colchicine 10 (2.0) 27 (3.2) 0.21 1.58
Metformin 40 (8.0) 212 (24.8) <0.001 58.57
Methotrexate 5 (1.0) 12 (1.4) 0.52 0.41
Spironolactone 44 (8.8) 143 (16.7) <0.001 16.55